The article focuses on the benefits for recurrent BRCA1 and BRCA2 founder mutations. Steven Narod and colleagues describe their 7-year experience offering founder mutation screening to more than 7000 Ashkenazi Jewish adults in the Ontario region of Canada. Cost and appropriate staffing or counselling guides are the remaining obstacles to population screening.